ESPE Abstracts (2014) 82 P-D-3-1-928

aPediatric Endocrinology, Kocaeli University, Kocaeli, Turkey; bZeynep Kamil Gynecologic and Pediatric Training and Research Hospital, Istanbull, Turkey

Objective: This study aims to reveal clinical, hormonal and ultrasound imaging features of patients treated with leuprolide acetate for diagnosis of precoccious puberty.

Design: Retrospective analysis of patients with a diagnosis of central precoccious puberty and treated with leuprolide acetate between January 2008 and January 2013.

Patients: 81 girls and two boys with early signs of puberty.

Results: There was a positive correlation between basal LH and peak LH/FSH values. An organic etiology was revealed in 14.8% of girl patients (hydrocephaly (7), meningomyelocele (2), hypophyseal tumor (2), rathke cleft cyst (1), and 50% of boys hamartoma (1)). The 50% of girls with organic etiology was >6 years. Majority of the patients were between 6 and 8 years old and idiopathic cases. Organic etiologies also can be seen in children older than 6 years old age, so kranial MR imaging may be indicated for selective cases >6 years old children (Table 1).

Table 1.
Patient number83
Mean age of first sign of puberty (years)6.66±1.87
Mean age of initiation of leuprolide acetate (years)7.78±1.82
Time to treatment (months)13.80±11.5
Height (S.D.)0.96±1.39
Weight (S.D.)1.29±1.16
Midparental height−0.82±0.95
Predicted adult height−0.86±1.46
Bone age9.78±2.22
Tanner stage at the initiation of treatment stage 2: 6 (7.3%); stage 3: 32 (39%); stage 4: 37 (45.1%); stage 5: 7(8.5%)
Mean uterine length on USG (mm)37.02±11.07
Mean ovary volüme (ml)2.89±2.22
Mean basal LH (mIU/ml)1.61±1.9
Mean peak LH on LHRH analog test (mIU/ml)12.46 (72% >5 mIU/ml)
Pubertal LH/FSH (>0.66) (%)42%
Mean bone age (years)9.78±2.22

Article tools

My recent searches

No recent searches.

My recently viewed abstracts